NFKB1 and B-cell chronic lymphocytic leukemia: Ibrutinib targets CLL through different mechanisms occurring mostly in tissues: induction of apoptosis, inhibition of proliferation by disruption of the BCR and NF-kB signaling pathways, impairment of adhesion and migration leading to leukemic cell egress from tissues to blood [8–13].